Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
Page 2

The organizers of the program hopes for the outcome of the project to have a substantial impact bioequivalence policy development for generic orally inhaled products.

Furthermore, the initiatives included under this funding opportunity announcement also intends to achieve the following objectives:

a) Develop a quality-by-design tool that could be utilized to improve the performance of orally inhaled drugs during the product development phase.

b) Determine accurate dose predictions.

c) Set clinical relevant aerodynamic particle size distribution specifications to ensure product quality, for these drug/device combination products.

To support these initiatives, the USFDA is ready to administer funds in the amount of $150,000.

The institutions and organizations who will be deemed eligible to submit an application under this program are the following:

a) Private and Public Non-profit entities

b) State and Local Governments

c) Indian Tribal Governments and Organizations

d) Faith-based Organizations

e) Community-based Organizations

f) Institutions of Higher Education

g) Private and Public Colleges and Universities

h) Independent School Districts

The Department of Health and Human Services, the mother agency funding the Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program, is the nation's leading agency for protecting the health of all Americans and providing fundamental human services to all.

Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Strategic Alliances for Medications Development to Treat Substance Use Disorder Program
The National Institutes of Health, in cooperation with the National Institute on Drug Abuse (NIDA), has recently established the Strategic Alliances for Medications Development to Treat Substance Use Disorder Program wherein both agencies seek to support the development of substance abuse drugs by leveraging the strengths of two or more organizations toward a common goal of medications development.

---

International Research Collaboration on Drug Abuse and Addiction
The National Institutes of Health, in collaboration with the National Institute on Drug Abuse (NIDA), has recently established the International Research Collaboration on Drug Abuse and Addiction Program wherein they seek to solicit collaborative research applications regarding addiction and drug use, through the utilization of special opportunities and resources that exist outside the United States of America.

---

Modeling Social Behavior Grant Program
The National Institutes of Health has collaborated with the National Institute of General Medical Sciences (NIGMS) and the National Institute of Mental Health (NIMH) in order to establish the Modeling Social Behavior Grant Program wherein they intend to seek applications for the development and evaluation of innovative theories, as well as computational, mathematical, and engineering approaches that could better our understanding of a human being's social behavior.

---

Biodemography of Aging Program
The National Institutes of Health has formed a partnership with the National Institute on Aging (NIA) in an effort to establish the Biodemography of Aging Program wherein they intend to solicit applications with the intent to conduct research studies regarding demographic and life-science approaches that could potentially expand the current understanding of aging, frailty and mortality.

---